Schachtel Bernard P, Homan Harvey D, Gibb Iain A, Christian Jenny
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA.
Clin Pharmacol Ther. 2002 May;71(5):375-80. doi: 10.1067/mcp.2002.124079.
The dose response of flurbiprofen lozenges (2.5, 5.0, and 12.5 mg) was evaluated in the treatment of sore throat. A refined version of the sore throat pain model showed that 12.5 mg flurbiprofen was significantly more effective than placebo at providing total pain relief and reducing throat soreness (p <.05). Flurbiprofen, 5.0 mg, was more effective than placebo for the reduction of throat soreness and the sensation of throat swelling (P <.05). The 2.5-mg flurbiprofen lozenge was indistinguishable from placebo. For every milligram of increase in the dose of flurbiprofen, there was an approximately 0.3-unit increase in total pain relief (P <.05). Flurbiprofen lozenges in all 3 dosages were well tolerated. Flurbiprofen lozenges are effective for sore throat at a dose between 5.0 mg and 12.5 mg; the sore throat pain model is a sensitive assay for demonstration of the dose-response relationship of an analgesic agent.
评估了氟比洛芬含片(2.5毫克、5.0毫克和12.5毫克)治疗喉咙痛的剂量反应。喉咙痛疼痛模型的改良版本显示,12.5毫克氟比洛芬在提供完全疼痛缓解和减轻喉咙疼痛方面比安慰剂显著更有效(p<.05)。5.0毫克氟比洛芬在减轻喉咙疼痛和喉咙肿胀感方面比安慰剂更有效(P<.05)。2.5毫克氟比洛芬含片与安慰剂无差异。氟比洛芬剂量每增加1毫克,总疼痛缓解约增加0.3个单位(P<.05)。所有3种剂量的氟比洛芬含片耐受性良好。5.0毫克至12.5毫克剂量的氟比洛芬含片对喉咙痛有效;喉咙痛疼痛模型是用于证明镇痛药剂量反应关系的灵敏测定方法。